Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2011 Oct 1;10(1):46–51. doi: 10.1016/j.cgh.2011.09.017

Figure 1.

Figure 1

Simplified model schematic showing the 2 treatment arms of IFX monotherapy and IFX + AZA combination therapy. When treatment is withdrawn because of a serious infection, other SAE, or because a patient is treatment refractory, then they remain in the moderate-severe disease activity state.